A 6-week, Double Masked, Placebo-controlled Study to Evaluate the Efficacy and Safety of Twice-daily Brinzolamide 1% / Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to Travoprost 0.004% in Reducing Intraocular Pressure in Patients With Normal Tension Glaucoma.

Trial Profile

A 6-week, Double Masked, Placebo-controlled Study to Evaluate the Efficacy and Safety of Twice-daily Brinzolamide 1% / Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to Travoprost 0.004% in Reducing Intraocular Pressure in Patients With Normal Tension Glaucoma.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Brimonidine/brinzolamide (Primary)
  • Indications Glaucoma
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 27 Sep 2017 Planned End Date changed from 16 May 2019 to 4 Jun 2019.
    • 27 Sep 2017 Planned primary completion date changed from 16 May 2019 to 4 Jun 2019.
    • 27 Sep 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top